Journal article
Mexiletine or catheter ablation after amiodarone failure in the VANISH trial
Abstract
INTRODUCTION: In patients with ischemic heart disease and ventricular tachycardia (VT) refractory to high dose amiodarone, the two most common therapeutic options are adjunctive mexiletine therapy or catheter ablation. There are little existing data on the efficacy of these strategies. We examined the relative efficacy of adjunctive mexiletine and catheter ablation among patients enrolled in the VANISH trial.
METHODS: All subjects enrolled in …
Authors
Deyell MW; Steinberg C; Doucette S; Parkash R; Nault I; Gray C; Essebag V; Gardner M; Sterns LD; Healey JS
Journal
Journal of Cardiovascular Electrophysiology, Vol. 29, No. 4, pp. 603–608
Publisher
Wiley
Publication Date
April 2018
DOI
10.1111/jce.13431
ISSN
1045-3873